Company No: 02102749 (England and Wales)

Contents

• Balance Sheet
• Notes to the Financial Statements

		2026		2025
		£		£
Fixed assets		504		138
Current assets		87,947		75,599
Creditors: amounts falling due within one year		( 194,569)		( 177,329)
Net current liabilities		( 106,622)		( 101,730)
Total assets less current liabilities		( 106,118)		( 101,592)
Creditors: amounts falling due after more than one year		-		( 612)
Accruals and deferred income		( 1,480)		( 1,649)
Net liabilities		( 107,598)		( 103,853)
Capital and reserves		( 107,598)		( 103,853)

For the financial year ending 31 January 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
• These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
• These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Marchbanks Measurement Systems Limited (registered number: 02102749) were approved and authorised for issue by the Board of Directors on 15 October 2026 and were signed on its behalf by:

Dr Robert James Marchbanks Director

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 02102749). The address of its registered office is Bryns-Dell House, St Mark's Road, Pennington, SO41 8HA, United Kingdom.

2. Employees

	2026		2025
	Number		Number
Monthly average number of persons employed by the Company during the financial year, including directors	2		2

3. Statement from the Board of Directors

Marchbanks Measurement Systems Ltd has developed unique instrumentation for the non-invasive measurement of cerebral and cochlear fluid pressure-related physiology. Innovate UK funding supported the design and development of the next-generation MMS-15 Analyser, together with clinical evaluation and the collection of normative data, and a UK patent has been granted for the MMS-15 design. The company continues to support scientific research using its technology, including research arising from deployment of the previous-generation MMS-14F Analyser on the International Space Station.

Progress continues towards proposed clinical research studies at University Hospital Southampton NHS Foundation Trust, including investigation of Normal Pressure Hydrocephalus and a Primary Care study examining physiological biomarkers associated with raised intracranial pressure. The company is also arranging discussions with the MHRA to clarify the regulatory requirements and terms under which existing stock MMS-14 and MMS-15 Analysers may be made available for use in these clinical research studies.

The company continues to support collaborative research with NHS and academic partners, including an ongoing research collaboration with Gloucestershire Hospitals NHS Foundation Trust. Alongside these activities, Marchbanks Measurement Systems Ltd continues to develop the scientific and clinical evidence base for tympanic membrane displacement measurement and to explore appropriate routes for the future commercialisation and wider international availability of its technology.

4. Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and will continue to support the company through their directors loan account. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.